ClinicalTrials.gg
RecruitingNCT07944235PREOPRADUpdated Nov 18, 2026

Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery

An interventional study of SRS and metastasectomy: surgical resection in Brain Neoplasms, Neoplasm Metastasis and Radiosurgery, sponsored by Fundacion Miguel Servet. Recruiting at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fundacion Miguel Servet · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 68 studies in Brain Neoplasms with a site in Spain — 13 open to participants now, 26 under way, 4 of them phase 3. Brain Neoplasms · Spain.

Planned enrollment
41st of 63
50 · median 72
Started
2026
with 3 others
No phase
4 of 68
4 open now
Primary completion
2030-03
later than 24 of 25 live
Registered
68th of 68
by date

Among the 68 studies in Brain Neoplasms with a site in Spain, this one is the 41st largest by planned enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 with no phase, reaches primary completion later than 24 of the 25 other live ones, and was the 68th registered.

Brain Neoplasms

2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

13 of the 68 studies in Brain Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Brain Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.

More specifically, the study seeks to:

  • Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
  • Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
  • Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.

PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.

The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.

Read the detailed description

Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.

03

Conditions studied

  • Brain Neoplasms
  • Neoplasm Metastasis
  • Radiosurgery
  • Neoadjuvant Therapy
  • Radiotherapy Adjuvant
  • Surgery

Keywords

  • neoplasms metastasis
  • radiosurgery
  • radiotherapy
  • radiomics
  • randomized
  • phase II/III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • confirmed solid tumor with one to four .
  • At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
  • Performance Status (KPS) ≥70.
  • ≥3 months.
  • Ability to undergo MRI examinations.
  • Written provided.

Exclusion criteria

Exclusion Criteria:

  • from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
  • Prior radiotherapy to the index lesion.
  • at baseline.
  • to surgery or stereotactic radiosurgery.
  • Pregnancy or breastfeeding.
  • Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    preoperative radiosurgery

    preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

    Radiation: SRS · Procedure: metastasectomy: surgical resection

  • Other
    postoperative radiosurgery

    standard treatment, consisting of surgical resection followed by irradiation of the tumor bed

    Radiation: SRS · Procedure: metastasectomy: surgical resection

Interventions

  • RadiationSRS

    radiosurgery (SRS) in patients with brain metastases who are candidates for surgery

    Also known as: radiosurgery

  • Proceduremetastasectomy: surgical resection

    Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm

06

What researchers measure

Primary outcomes

  1. Locoregional adverse event-free survival

    A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed.

    Time frame: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization

Secondary outcomes

  1. Meningeal Failure Rate

    Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI).

    Time frame: 6 and 12 months after randomization.

  2. Symptomatic Radiation Necrosis Rate

    Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation.

    Time frame: 6 and 12 months after randomization.

  3. Local Control Rate

    Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI.

    Time frame: 6 and 12 months after randomization.

  4. Distant Brain Failure-Free Survival

    Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s).

    Time frame: 6 and 12 months after randomization.

  5. Overall Survival

    Time from randomization to death from any cause.

    Time frame: 6 and 12 months after randomization.

Other outcomes

  1. Time to Whole-Brain Radiotherapy (WBRT)

    Time from randomization to the administration of whole-brain radiotherapy (WBRT).

    Time frame: From randomization until administration of WBRT, up to 42 months.

  2. Health-Related Quality of Life

    Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden).

    Time frame: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.

  3. Length of Hospital Stay

    Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge.

    Time frame: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.

  4. Treatment Delay

    Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment.

    Time frame: From treatment planning to treatment completion, up to 42 months.

07

Study locations

2 of 5 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2030, 42 months after the start.

Of 308 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 42 months is below that.

Counting every sponsor, half of 319 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Mar 30, 2030
CompletionEst.
Mar 31, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07944235
Lead sponsor
Fundacion Miguel Servet
Collaborators
Hospital Ruber Internacional, University of Salamanca, Hospital de Meixoeiro, Hospital Universitario de Badajoz, Hospital Universitario Ramon y Cajal, Hospital of Navarra, Centro de Investigación Médica Aplicada (CIMA), Universidad de Brescia
Responsible party
Paola Anna Jablonska (Consultant Physician, Fundacion Miguel Servet) — Principal investigator
First posted
Nov 18, 2026
Start date
Sep 30, 2026
Primary completion
Mar 30, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion